The Week in Cancer News: Treating Rare Blood Cancers
The FDA approves two therapies to treat rare blood cancers, and U.S. cervical cancer screening rates decline.
Progress Against Cancer
The FDA approves two therapies to treat rare blood cancers, and U.S. cervical cancer screening rates decline.
Recent reporting and rumors may have one believe that cigarettes are cool and popular again among young Americans. The data don’t bear this out—fewer young people smoke than ever—but a reminder of smoking’s dangers...
Ropeginterferon alfa-2b-njft treats essential thrombocythemia by targeting blood-forming cells in the bone marrow. The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) injection to treat adults with a rare blood cancer,...
Cancer Research Catalyst has launched a new monthly series, “Unboxing Cancer News,” that highlights exciting cancer research discoveries. Read the first installment and learn about transmissible cancer in catfish, federal- vs. industry-sponsored trials, symptoms...
Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo) for adult patients with polycythemia vera, a rare, slow-growing blood cancer that causes excessive blood...
The FDA approves a RAS-targeted therapy, and government-funded research explores topics often neglected by industry trials.
Daraxonrasib is approved for previously treated or systemic-therapy-ineligible metastatic pancreatic adenocarcinoma. The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma whose cancer has progressed following at...
Two zanidatamab-based regimens were approved for certain HER2-positive advanced gastric, gastroesophageal junction, or esophageal cancers. The U.S. Food and Drug Administration (FDA) has approved zanidatamab-hrii (Ziihera) as part of two first-line treatment regimens for...
Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these hurdles. Learn about recent efforts...
The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More